125 related articles for article (PubMed ID: 8695157)
1. Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer.
Ferrigno D; Buccheri G
Acta Oncol; 1996; 35(4):435-9. PubMed ID: 8695157
[TBL] [Abstract][Full Text] [Related]
2. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
[TBL] [Abstract][Full Text] [Related]
4. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1).
Booton R; Lorigan P; Anderson H; Baka S; Ashcroft L; Nicolson M; O'Brien M; Dunlop D; O'Byrne K; Laurence V; Snee M; Dark G; Thatcher N
Ann Oncol; 2006 Jul; 17(7):1111-9. PubMed ID: 16603599
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
González Barón M; Feliu J; Espinosa E; García Girón C; Blanco E; Garrido P; Colmenarejo A; Ordóñez A; Moyano A; de la Gándara I
Ann Oncol; 1994 Apr; 5(4):323-7. PubMed ID: 8075028
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
Bonomi PD; Finkelstein DM; Ruckdeschel JC; Blum RH; Green MD; Mason B; Hahn R; Tormey DC; Harris J; Comis R
J Clin Oncol; 1989 Nov; 7(11):1602-13. PubMed ID: 2553879
[TBL] [Abstract][Full Text] [Related]
8. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomised trial. The "Gruppo Oncologico Centro-Sud-Isole' (G.O.C.S.I.).
Gridelli C; Perrone F; Palmeri S; D'Aprile M; Cognetti F; Rossi A; Gebbia V; Pepe R; Veltri E; Airoma G; Russo A; Incoronato P; Scinto AF; Palazzolo G; Natali M; Leonardi V; Gallo C; De Placido S; Bianco AR
Ann Oncol; 1996 Oct; 7(8):821-6. PubMed ID: 8922196
[TBL] [Abstract][Full Text] [Related]
9. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
[TBL] [Abstract][Full Text] [Related]
10. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
11. A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma.
Veeder MH; Jett JR; Su JQ; Mailliard JA; Foley JF; Dalton RJ; Etzell PS; Marschke RF; Kardinal CG; Maksymiuk AW
Cancer; 1992 Nov; 70(9):2281-7. PubMed ID: 1394057
[TBL] [Abstract][Full Text] [Related]
12. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer.
Ellis PA; Smith IE; Hardy JR; Nicolson MC; Talbot DC; Ashley SE; Priest K
Br J Cancer; 1995 Feb; 71(2):366-70. PubMed ID: 7530988
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients.
Felip E; Del Campo JM; Bodi R; Vera R; Casado S; Rubio D
Am J Clin Oncol; 1997 Aug; 20(4):404-6. PubMed ID: 9256899
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Kucuk O; Shevrin DH; Pandya KJ; Bonomi PD
Am J Clin Oncol; 2000 Aug; 23(4):371-5. PubMed ID: 10955866
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.
Richards F; Perry DJ; Goutsou M; Modeas C; Muchmore E; Rege V; Chahinian AP; Hirsh V; Poiesz B; Green MR
Cancer; 1991 Jun; 67(12):2974-9. PubMed ID: 1646066
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of dose intensification with cisplatin and carboplatin plus vindesine in patients with inoperable non-small cell lung cancer.
Nakanishi Y; Takayama K; Kawasaki M; Yatsunami J; Inutsuka S; Wakamatsu K; Tsuruta N; Hara N
Am J Clin Oncol; 1997 Aug; 20(4):393-7. PubMed ID: 9256897
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group.
Buccheri G; Ferrigno D
Lung Cancer; 1997 Aug; 18(1):57-70. PubMed ID: 9268948
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
Crinò L; Clerici M; Figoli F; Carlini P; Ceci G; Cortesi E; Carpi A; Santini A; Di Costanzo F; Boni C
Ann Oncol; 1995 Apr; 6(4):347-53. PubMed ID: 7619749
[TBL] [Abstract][Full Text] [Related]
20. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
